A clinical-stage gene therapy company striving to halt or reverse
disease with a single dose.
We are AVROBIO
Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease and cystinosis, as well as preclinical programs for Hunter syndrome and Pompe disease. Our proprietary plato® gene therapy platform is scalable for planned global commercialization. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com and follow us on Twitter and LinkedIn.
Sign up for email alerts
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Cowen’s 43rd Annual Health Care Conference
Gaucher Disease Program Update
Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to initiate
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 3, 2023-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled
Four platform presentations and two posters with data on AVROBIO’s lysosomal disorder programs to be presented CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 9, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease,
Westwicke Partners for AVROBIO